AEGiS-APPJ: Determining Allocations for HIV-Prevention Interventions: Assessing a Change in Federal Funding Policy

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Determining Allocations for HIV-Prevention Interventions: Assessing a Change in Federal Funding Policy

AIDS & Public Policy Journal 12, no. 4 (Winter 1997): 138
R.O. Valdiserri et al.

In January 1994, the Centers for Disease Control and Prevention (CDC) mandated that health departments that received federal funds for the prevention of transmission of HIV to undertake a new approach in planning programs to prevent the transmission of HIV and setting priorities for these programs: HIV Prevention Community Planning. Briefly, community planning is a cyclical, evidence-based planning process in which authority for identifying priorities for funding HIV-prevention programs is vested in one or more planning groups in each jurisdiction (that is, in each state or local health department) that receives HIV-prevention funds from CDC. Planning groups are composed of community representatives (particularly communities affected by the HIV epidemic); scientists and other technical experts (especially epidemiologists and behavioral scientists); and staff of nongovernmental organizations and departments of health and education, and substance-abuse prevention.

Prior to the implementation of this program, CDC, under direction of the U.S. Congress, had awarded funds to health departments in several fixed intervention/programmatic categories, including HIV counseling, testing, referral, and partner-notification programs (CTRPN); health education and risk-reduction programs (HERR); public information programs (PI); and program initiatives for HIV prevention in racial and ethnic minority communities (MI). CTRPN was, by far, the largest of these categories, accounting for over two-thirds of the $157,188,492 awarded to state and local health departments for HIV-prevention activities in fiscal year (FY) 1993.
971215
APPJ97120403

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1986, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .